Intragastric Balloon Versus Endoscopic Sleeve Gastroplasty for the Treatment of Obesity: a Systematic Review and Meta-analysis.
ESG
Endoscopic and bariatric therapy
Endoscopic sleeve gastroplasty
Gastric balloon
IGB
Intragastric balloon
Obesity
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
14
5
2020
medline:
15
4
2021
entrez:
14
5
2020
Statut:
ppublish
Résumé
We aimed to individually evaluate IGB and ESG procedures and compare the efficacy, durability, and safety of these procedures. Bibliographic databases were systematically searched for studies investigating the use of IGB and ESG for the treatment of obesity. Studies reporting percent total weight loss (%TWL) or percent excess weight loss (%EWL) with at least 12 months of follow-up were included. A total of 28 studies were included in the final analysis. Only 1 study directly compared ESG to IGB, 9 studies evaluated ESG alone, while 18 studies evaluated IGB. At 12-month follow-up after ESG, mean %TWL was 17.51 (95% CI 16.44-18.58), and %EWL was 60.51 (95% CI 54.39-66.64). Mean %TWL and %EWL after IGB at 12 months was 10.35 (95% CI 8.38-12.32) and 29.65 (95% CI 25.40-33.91), respectively. Mean %TWL and %EWL after IGB were significantly decreased at 18 or 24 months compared to 6 months indicating weight regain after IGB removal. ESG achieved significantly superior weight loss compared to IGB, the difference in mean %TWL was 7.33 (95% CI 5.22-9.44, p value = 0.0001) at 12 months. Serious adverse events were observed in < 5% for both procedures. Although ESG and IGB are safe and effective for weight loss, our study suggests that ESG results in more significant and sustained weight loss. Nevertheless, a variety of approaches are essential to care for this underserved population, and there are several factors other than weight loss that should be considered in selecting the ideal therapy for individual patients.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to individually evaluate IGB and ESG procedures and compare the efficacy, durability, and safety of these procedures.
METHODS
METHODS
Bibliographic databases were systematically searched for studies investigating the use of IGB and ESG for the treatment of obesity. Studies reporting percent total weight loss (%TWL) or percent excess weight loss (%EWL) with at least 12 months of follow-up were included.
RESULTS
RESULTS
A total of 28 studies were included in the final analysis. Only 1 study directly compared ESG to IGB, 9 studies evaluated ESG alone, while 18 studies evaluated IGB. At 12-month follow-up after ESG, mean %TWL was 17.51 (95% CI 16.44-18.58), and %EWL was 60.51 (95% CI 54.39-66.64). Mean %TWL and %EWL after IGB at 12 months was 10.35 (95% CI 8.38-12.32) and 29.65 (95% CI 25.40-33.91), respectively. Mean %TWL and %EWL after IGB were significantly decreased at 18 or 24 months compared to 6 months indicating weight regain after IGB removal. ESG achieved significantly superior weight loss compared to IGB, the difference in mean %TWL was 7.33 (95% CI 5.22-9.44, p value = 0.0001) at 12 months. Serious adverse events were observed in < 5% for both procedures.
CONCLUSION
CONCLUSIONS
Although ESG and IGB are safe and effective for weight loss, our study suggests that ESG results in more significant and sustained weight loss. Nevertheless, a variety of approaches are essential to care for this underserved population, and there are several factors other than weight loss that should be considered in selecting the ideal therapy for individual patients.
Identifiants
pubmed: 32399847
doi: 10.1007/s11695-020-04644-8
pii: 10.1007/s11695-020-04644-8
pmc: PMC7720242
mid: NIHMS1648584
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3010-3029Subventions
Organisme : NIGMS NIH HHS
ID : U54 GM104942
Pays : United States
Références
Obes Surg. 2010 Aug;20(8):1128-32
pubmed: 19015930
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
Gastrointest Endosc. 2015 Sep;82(3):425-38.e5
pubmed: 26232362
Gastrointest Endosc. 2019 Nov;90(5):770-780
pubmed: 31228432
Am J Gastroenterol. 2019 Sep;114(9):1421-1431
pubmed: 31082868
Dig Endosc. 2020 May;32(4):541-546
pubmed: 31394006
Obes Surg. 2020 May;30(5):1971-1987
pubmed: 32107706
Obes Surg. 2009 Aug;19(8):1084-8
pubmed: 19506981
Surg Endosc. 2020 Oct;34(10):4388-4394
pubmed: 31624939
Int J Obes (Lond). 2017 Mar;41(3):427-433
pubmed: 28017964
Obes Surg. 2013 Jul;23(7):892-6
pubmed: 23404240
Obes Surg. 2012 Apr;22(4):565-71
pubmed: 21901285
Surg Endosc. 2018 Sep;32(9):3936-3942
pubmed: 29492709
Surg Endosc. 2009 Aug;23(8):1849-53
pubmed: 19169745
Obes Surg. 2005 Jun-Jul;15(6):864-70
pubmed: 15978160
Adv Ther. 2017 Aug;34(8):1859-1875
pubmed: 28707286
Clin Gastroenterol Hepatol. 2017 Jan;15(1):37-43.e1
pubmed: 26748219
Obes Surg. 2013 Apr;23(4):427-36
pubmed: 23338049
Surg Endosc. 2018 Apr;32(4):2159-2164
pubmed: 29075966
Surg Obes Relat Dis. 2016 Feb;12(2):420-9
pubmed: 26968503
Obes Surg. 2008 Aug;18(8):989-92
pubmed: 18483834
Gastrointest Endosc. 2018 Feb;87(2):442-447
pubmed: 28843586
Obes Surg. 2019 Nov;29(11):3547-3552
pubmed: 31214968
Obes Surg. 2012 Jun;22(6):896-903
pubmed: 22287051
Obesity (Silver Spring). 2013 Aug;21(8):1561-70
pubmed: 23512773
Obes Surg. 2018 Sep;28(9):2617-2625
pubmed: 29663250
Endoscopy. 2019 Jun;51(6):532-539
pubmed: 30841009
Obes Surg. 2015 Oct;25(10):1842-7
pubmed: 25812529
Gastrointest Endosc. 2011 Nov;74(5):943-53
pubmed: 22032311
Diabetes Metab Syndr Obes. 2017 Jul 06;10:311-316
pubmed: 28740414
Arq Bras Cir Dig. 2017 Jan-Mar;30(1):18-20
pubmed: 28489162
Surg Obes Relat Dis. 2020 Feb;16(2):340-351
pubmed: 31932205
Obes Surg. 2019 Jun;29(6):1932-1936
pubmed: 30806915
Gastrointest Endosc. 2019 Jun;89(6):1132-1138
pubmed: 30578757
Obes Surg. 2011 Oct;21(10):1597-604
pubmed: 21494811
Obes Surg. 2013 Apr;23(4):515-21
pubmed: 23224509
Obes Surg. 2006 Sep;16(9):1135-7
pubmed: 16989695
Obes Surg. 2018 Jul;28(7):1812-1821
pubmed: 29450845
Clin Gastroenterol Hepatol. 2018 Jul;16(7):1081-1088.e1
pubmed: 29481969
Obes Surg. 2010 Sep;20(9):1219-26
pubmed: 18752030
Obes Surg. 2020 Jul;30(7):2743-2753
pubmed: 32300945
Surg Obes Relat Dis. 2018 Nov;14(11):1691-1699
pubmed: 30193905
Obes Surg. 2004 Aug;14(7):991-8
pubmed: 15329191